Certain rare epidermal growth factor receptor (EGFR) mutations are associated with tobacco smoking, worse prognosis and poor response to EGFR tyrosine kinase inhibitor (TKI) therapy compared to the more common “classical” EGFR mutations. However, as not all rare mutations are the same, testing and therapy may need to be evaluated for each individual mutation.
Multiplexed genetic screening for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) gene rearrangements and subsequent biomarker-guided treatment is cost-effective compared with standard chemotherapy treatment without any molecular testing in the metastatic non-small cell lung cancer (NSCLC) setting in the United States.
A survey of the general population in France identifies knowledge gaps in the perception of lung cancer.
DENVER – A prospective nationwide survey on perceptions of lung cancer in the general population of France highlights a need for increased public education on the benefits of lung cancer screening, the good survival rates of early-stage disease and the improved outcomes with new therapeutic strategies, including targeted-therapies.
Targeted next-generation sequencing reveals a high number of genomic mutations in advanced malignant plural mesothelioma.
DENVER – Next generation sequencing in malignant pleural mesothelioma (MPM) tumors shows a complex mutational setting with a high number of genetic alterations in genes involved in DNA repair, cell survival and cell proliferation pathways. Increased accumulation of mutations correlates with early progression of the tumor and decreased survival.
DENVER – The International Association for the Study of Lung Cancer (IASLC) is pleased that the Centers for Medicare & Medicaid Services (CMS) made a draft proposal Monday to cover low-dose CT screening of patients at high risk for lung cancer.
Interstitial lung disease is a significant risk factor for lung inflammation following stereotactic body radiation therapy for lung cancer.
DENVER – Pretreatment interstitial lung disease (ILD) is a significant risk factor for developing symptomatic and severe radiation pneumonitis in stage I non-small cell lung cancer (NSCLC) patients treated with stereotactic body radiation therapy (SBRT) alone.